Anteris Technologies Global Corp. · NASDAQ:AVR

Anteris Technologies Global — Symposium on Next Generation Technologies (July 2020)

11 slides from Anteris Technologies Global's conference presentation, Jul 21, 2020

  1. Slide 1: DurAVR built with ADAPT technology

    For personal use only DurAVR™ built with ADAPT® technology Creating the world’s most durable valve www.anteristech.com | Follow us @anteristech Copyright Anteris Technologies Ltd 2020

  2. Slide 2: The TAVR market is growing significantly

    The TAVR market is growing significantly use only Market Potential of AVR as TAVR 15.6% For personal Treatment of Severe Aortic By 2025, Global Aortic CAGR Stenosis(SAS) Valve Replacement to $10 reach Billions $8B USD* $5 $6.9B $2.5B $- TAVR is expected to be 62% of $1.1B $1.1B procedure volume and

  3. Slide 3: DurAVR: A unique 3D single-piece Aortic Valve Replacement

    For personal use only DurAVR™ A unique 3D single- piece Aortic Valve Replacement

  4. Slide 4: Designed to Last Longer and Work Better

    DurAVR™ Designed to Last Longer and Work Better (3) (4,5) DurAVR™ For personal use only (an ADAPT® product) Lasts Longer (3) Works Better Durability = full function over time (a)+(b) = Better hemodynamics = Better outcomes (a) No calcification (b) Less mechanical stress Lower mean gradient* Larger E

  5. Slide 5: ADAPT Tissue Science

    For personal use only ADAPT® TISSUE SCIENCE First and only anti-calcification treatment demonstrating zero calcification in humans beyond 10 years

  6. Slide 6: ADAPT is widely studied and used in over 20,000 patients

    ADAPT® is widely studied and has been used in over 20,000 patients worldwide For personal use only ü >20,000 implants in young patients with congenital heart disease ü 10-year clinical data with no calcification in pediatric patients ü Largest series is 500 patients Publications include manuscripts,

  7. Slide 7: Accelerated wear testing and sheep calcification model

    DurAVR™ shows zero wear in accelerated testing equivalent to 12 years For personal use only ACCELERATED WEAR TESTING SHEEP CALCIFICATION MODEL Anteris Valve shows no wear at 550 million cycles Well Anchored Supple Clean Margins Day 1 200 million 500 million Sutures Cusps (Annulus) Competitor Valves

  8. Slide 8: Promises best in class hemodynamics

    DurAVR™ promises best in class hemodynamics For personal use only Design Option Inner Diameter of Annulus or ΔPmean (mmHg) EOA (cm2) Surgical Valve(mm) DurAVR™ 23 4.89 3.07 (25MM) 21 5.17 3.04 DurAVR™ 23 5.34 3.26 (25 MM) 21 3.86 3.28 COREVALVE* 7.76 ± 0.14 1.66 ± 0.05 (26MM) 21 (True ID of 23mm Per

  9. Slide 9: First in Human study patient #1

    DurAVR™ First in Human study patient #1 For personal use only “I have not seen these kind of results with commercially available valves” - Prof Bart Meuris Patients with DurAVR™ other surgical Patient 1 valves* (N>1400) Peak Gradient 23 11 mmHg Mean Gradient 11 5 mmHg EOA cm2 1.9 2.9 * Average of 14

  10. Slide 10: Designed to Last Longer and Work Better

    DurAVR™ Designed to Last Longer and Work Better (3) (4,5) DurAVR™ For personal use only (an ADAPT® product) Lasts Longer (3) Works Better Durability = full function over time (a)+(b) = Better hemodynamics = Better outcomes (a) No calcification (b) Less mechanical stress Lower mean gradient* Larger E

  11. Slide 11: Developing the world's most durable heart valve

    Developing the world’s most durable heart valve For personal use only The right science • ADAPT® anti-calcification treatment is proven over 10 years in humans, with zero calcification in published studies. • Zero DNA • Zero residual glutaraldehyde The right design • The DurAVR™ 3D single-piece valv

Anteris Technologies Global — Symposium on Next Generation Technologies (July 2020) on 6ix